Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Maoxi Zhong"'
Publikováno v:
Frontiers in Molecular Biosciences, Vol 8 (2021)
Background: Gastrointestinal cancers patients might experience multiple primary tumors in the digestive tract. Therefore, identifying potential biomarkers can help us better understand the underlying mechanism. From the GEO database, four profiles of
Externí odkaz:
https://doaj.org/article/2f52fde0ae4040f09c7b7c8cb1fa3862
Publikováno v:
Journal of Cellular and Molecular Medicine. 25:4136-4147
In recent years, although Immune Checkpoint Inhibitors (ICIs) significantly improves survival both in local advanced stage and advanced stage of non-small cell lung cancer (NSCLC), the objective response rate of ICI monotherapy is still only about 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a89923310eb7ff5f44f7f7e12b455890
https://doi.org/10.1111/jcmm.16383
https://doi.org/10.1111/jcmm.16383
Autor:
Zhi, Wang, Lingling, Zhang, Wenwen, Xu, Jie, Li, Yi, Liu, Xiaozhu, Zeng, Maoxi, Zhong, Yuxi, Zhu
Publikováno v:
Journal of inflammation research. 15
Lung cancer is a high-risk malignancy worldwide. The harboring of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) makes EGFR-tyrosine kinase inhibitor (EGFR-TKI) an attractive therapeutic option. However, patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::26fb587db052a5bfd7183870dd43aeed
https://pubmed.ncbi.nlm.nih.gov/35140497
https://pubmed.ncbi.nlm.nih.gov/35140497
Objective The protein encoded by collagen type I alpha 1 chain(COL1A1)is a component of the extracellular matrix, and critical for tumor microenvironments. However, it remains unclear that the expression level, prognostic prediction, and immunologica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4185adcc4436bc6f38220625d5f8e0aa
https://doi.org/10.21203/rs.3.rs-293163/v1
https://doi.org/10.21203/rs.3.rs-293163/v1
Background: Patients with advanced gastroesophageal cancer refractory to previous regimen of chemotherapy suffered from poor prognosis without many effective treatment options. Immune checkpoint inhibitors (ICIs) provide promising efficacy, but the r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36c179f95e70ef2b36260ca110d986ec
https://doi.org/10.21203/rs.3.rs-156048/v1
https://doi.org/10.21203/rs.3.rs-156048/v1
Publikováno v:
Journal of Cellular and Molecular Medicine
In recent years, although Immune Checkpoint Inhibitors (ICIs) significantly improves survival both in local advanced stage and advanced stage of non‐small cell lung cancer (NSCLC), the objective response rate of ICI monotherapy is still only about
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5c95e5f96a157966fe9ff6c325fb290a
https://pubmed.ncbi.nlm.nih.gov/33630417
https://pubmed.ncbi.nlm.nih.gov/33630417
Publikováno v:
OncoTargets and therapy
Apatinib (Aitan®, brand name in China) is a new anti-antiangiogenic agent that has recently been approved for the treatment of advanced gastric cancer (GC) in China. Nevertheless, its therapeutic efficacy against other types of advanced solid tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e06e462ab83c01c1b818b69aab00597
https://pubmed.ncbi.nlm.nih.gov/30288047
https://pubmed.ncbi.nlm.nih.gov/30288047
Autor:
Maoxi Z; Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.; Department of Oncology, Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.; Chongqing Clinical Cancer Research Center, Chongqing, China., Jinmin X; Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.; Department of Oncology, Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.; Chongqing Clinical Cancer Research Center, Chongqing, China., Xiaozhu Z; Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.; Department of Oncology, Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.; Chongqing Clinical Cancer Research Center, Chongqing, China., Yubing Y; Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.; Department of Oncology, Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.; Chongqing Clinical Cancer Research Center, Chongqing, China., Yuxi Z; Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.; Department of Oncology, Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.; Chongqing Clinical Cancer Research Center, Chongqing, China.
Publikováno v:
Journal of oncology [J Oncol] 2021 Sep 16; Vol. 2021, pp. 3048974. Date of Electronic Publication: 2021 Sep 16 (Print Publication: 2021).